Patient Enrollment Begins for Australian Trial

May 11, 2020

Patient Enrollment Begins for Australian Trial

Mesoblast, a Melbourne-based biotech company, began enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L for the treatment of COVID-19. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months. Yourway is equipped to handle and transport sensitive clinical trial materials, including cell and gene therapies.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Media

Articles

Global Reach in Clinical Trials: Beyond Presence to True Execution

Open chat

Hello! How can I help you?